DIOVAN Drug Patent Profile

When do Diovan patents expire, and when can generic versions of Diovan launch?

Diovan is a drug marketed by Novartis and is included in three NDAs.

The generic ingredient in DIOVAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.

Summary for DIOVAN

US Patents:	0
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIOVAN

Paragraph IV (Patent) Challenges for DIOVAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIOVAN	Tablets	valsartan	40 mg, 80 mg, 160 mg and 320 mg	021283	1	2004-12-28

US Patents and Regulatory Information for DIOVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	DIOVAN	valsartan	CAPSULE;ORAL	020665-001	Dec 23, 1996		DISCN	No	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-001	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-001	Jul 18, 2001	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-002	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN	valsartan	CAPSULE;ORAL	020665-002	Dec 23, 1996		DISCN	No	No

International Patents for DIOVAN

See the table below for patents covering DIOVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	986056
Russian Federation	2203054	ТВЕРДЫЕ ОРАЛЬНЫЕ ДОЗИРУМЫЕ ФОРМЫ НА ОСНОВЕ ВАЛЬСАРТАНА (SOLID ORAL DOSED VALSARTAN-BASED FORMS)
South Korea	20060079260
Finland	107921
South Korea	100792389

Supplementary Protection Certificates for DIOVAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1467728	300811	Netherlands		PRODUCT NAME: SACUBITRIL/VALSARTAN, MET INBEGRIP VAN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/15/1058 (C(2015) 8288) 20151123
1948158	PA2016017	Lithuania		PRODUCT NAME: SAKUBITRILAS/VALSARTANAS; REGISTRATION NO/DATE: EU/1/15/1058 20151119
0443983	97C0039	Belgium		PRODUCT NAME: VALSARTAN; NAT. REGISTRATION NO/DATE: 206 IS 239 F 4 19970520; FIRST REGISTRATION: DE 36983.00.00 19960513
2340828	301088	Netherlands		PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, DAT WIL ZEGGEN (((S)-N-VALERYL-N-((2'-(1H-TETRAZOL-5-YL)-BIFENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIFENYL-4-YL-4-(3-CARBOXYPROPIONYLAMINO)-2-METHYL-PENTAANZUURETHYLESTER))NA3-X H2O, WAARBIJ X 0 TOT EN MET 3 IS; REGISTRATION NO/DATE: EU/1/15/1058 20151123
0443983	98C004	Belgium		PRODUCT NAME: VALSARTAN HYDROCHLOROTHIAZIDUM; NATL. REGISTRATION NO/DATE: 206 IS 250 F 3 19980624; FIRST REGISTRATION: FR 344300.5 19970925

Investment Scenario, Market Dynamics, and Financial Trajectory for DIOVAN (Valsartan)

Last updated: February 3, 2026

Executive Summary

DIOVAN (valsartan), an angiotensin II receptor blocker (ARB), has been a pivotal antihypertensive medication since its FDA approval in 1995. Its market trajectory has experienced significant fluctuations, influenced by patent status, regulatory actions, and competitive dynamics. Presently, DIOVAN's revenue trajectory is impacted by patent expirations, generic competition, and ongoing litigation related to its prior association with drug recalls. This report provides a comprehensive analysis of the current investment landscape, market forces, and financial outlook for DIOVAN, enabling stakeholders to make informed strategic decisions.

---

1. Market Overview of DIOVAN (Valsartan)

Parameter	Details
Therapeutic Class	Angiotensin II receptor blocker (ARB)
Primary Indications	Hypertension, Heart failure, Post-myocardial infarction
Initial FDA Approval	1995 (Novartis/Sandoz)
Patent Expiry	2010 (primary patent expired in 2012)
Major Manufacturer(s)	Novartis, subsequently generics from multiple manufacturers post-2012

1.1. Market Size & Growth

• Global Hypertension Market (2022): Estimated at USD 44 billion,[1] with DIOVAN accounting for an estimated 12-15% share pre-generic entry.
• DIOVAN's Peak Revenue: Approx. USD 4.4 billion (2010), prior to patent expiry.[2]
• Post-Patent Revenue Decline: Following patent expiry, revenue declined by approximately 60% within five years, primarily replaced by generics.
• Current Market Penetration: Generic versions dominate, with Novartis' branded DIOVAN representing less than 10% of the total ARB market share.

1.2. Patent and Regulatory Milestones

Year	Event	Impact
2010	Patent expiration in the US	Entry of generics
2012	Worldwide patent lapses	Surge in generic competition
2018	Teva sues FDA over labeling	Regulatory challenges and market hesitance
2019	Recall of valsartan-containing drugs (N-Nitrosodimethylamine, NDEA contamination)	Regulatory scrutiny, reputation impact

---

2. Current Investment Scenario

Aspect	Details
Patent & Exclusivity Status	Patent expired in 2010; no market exclusivity remains for DIOVAN in major markets
Generic Competition	Dominant; >90% market share held by generics in key markets (US, EU)
Revenue Trends	Steady decline since 2012; recent stabilization with high-potency formulations and specific indications
Legal & Regulatory Factors	Ongoing litigation from earlier recalls; regulatory agencies have increased scrutiny of valsartan manufacturing companies
Pipeline & Formulation Innovations	Opportunities in combination therapies (e.g., ARNI + ARB), improved formulations (e.g., extended-release)

2.1. Investment Risks

Risk Factor	Impact	Mitigation Strategy
Patent expiry in key markets	Revenue erosion	Diversify portfolio, focus on biosimilars and fixed-dose combinations
Regulatory recalls & scrutiny	Reputational risk, liability	Engage with compliant manufacturing, transparent reporting
Competition from novel agents	Market share erosion	Accelerate pipeline development, differentiated formulations

2.2. Investment Opportunities

Opportunity	Description	Particulars
Branded vs. Generic Play	Capitalize on branded formulations for niche markets	Focus on regions with brand loyalty (e.g., Japan)
Combination Drugs	Develop fixed-dose combinations (FDCs)	e.g., valsartan + amlodipine, leveraging existing formulations
Biosimilars & Generics	Enter biosimilar markets	Expand into biosimilar ARBs in emerging markets
Digital & Remote Monitoring	Telemedicine integrations	Offer value-added services in hypertension management

---

3. Market Dynamics Influencing DIOVAN's Financial Trajectory

3.1. Patent and Market Exclusivity Trends

The decline of DIOVAN's revenue stems primarily from patent expiration and the advent of generics. The transition illustrates classic revenue erosion:

Year	Revenue (USD Million)	Market Share	Notes
2010	4,400	35%	Peak revenue pre-patent expiry
2012	1,200	10-12%	Patent expiry impacts
2015	600	<5%	Generic dominance established

3.2. Regulatory Environment and Litigation Impact

• The 2018 recall of valsartan medicines due to NDMA and NDEA contaminants [3] led to increased regulatory oversight, deterring potential new formulations and possibly increasing legal liabilities.
• Ongoing litigation related to manufacturing defects and contamination demands legal costs, providing a risk-adjusted valuation for investors.

3.3. Competitive Landscape

Competitor	Market Share	Key Differentiators	Strategy
Generic manufacturers	90-95%	Price competitiveness	Cost leadership
Novartis (branded DIOVAN)	<10%	Brand loyalty, clinical data	Niche marketing, innovation

3.4. Pricing Trends

Period	Price Trend	Impact
2010-2012	Sharp decline	Entry of generics reduces revenue
2015-2020	Stabilized	Price erosion plateaued; premium on formulations or specific indications

3.5. Emerging Market Dynamics

• Rising hypertension prevalence in emerging markets (India, China) presents growth opportunities for low-cost generics.
• Regulatory harmonization efforts (e.g., ICH guidelines) facilitate market entry but also increase compliance costs.

---

4. Financial Trajectory Projections

4.1. Revenue Forecast

Year	Revenue Projection	Assumptions	Notes
2023	USD 500-700 million	Stabilized generics, minimal new formulations	Continued decline, plateauing
2025	USD 400-600 million	Market saturation, regulatory constraints	Slight decline expected
2030	USD 300-500 million	Diversification into FDCs, biosimilars	Longer-term revenue stabilization

4.2. Profitability and Cost Structure

Aspect	2023 Estimate	Notes
Gross Margin	20-25%	Low due to generic pricing pressures
R&D Expense	3-5% revenue	Focused on formulations, lifecycle management
Operating Margin	Negative to low positive	Cost containment critical

4.3. Valuation Considerations

• Market capitalization for Novartis' ARB segment declined post-patent expiry.
• Investment in pipeline products and FDCs could lead to revenue resurgence.
• Replacement cost of manufacturing facilities and ongoing legal liabilities influence valuation.

---

5. Comparative Analysis with Other ARBs

Drug	Patent Expiry	2022 Global Sales (USD Million)	Market Share (Estimated)	Key Differentiators
DIOVAN	2010	600	10-12%	Established brand, niche markets
Benezartan	2014	200	3-4%	Emerging markets focus
Candesartan	2012	1,000	15%	Longer patent life, strong clinical data
Olmesartan	2010	1,200	20%	Potent, once-daily dosing

This comparison indicates relative market positioning and helps evaluate future growth potential.

---

6. Key Policy & Regulatory Trends

Policy Area	Impact	Future Outlook
Patent legislation	Shortening of patent life in some jurisdictions	Increased generic penetration
Pricing regulations	Price controls in Europe and emerging markets	Margins compressed, focus on volume
Contaminant regulation	Stricter standards for NDMA/NDEA	Higher manufacturing compliance costs

---

7. Deep-Dive: Opportunities in Drug Development & Portfolio Expansion

Strategy	Details	Expected Outcomes
Fixed-Dose Combinations	Valsartan+Amlodipine, Valsartan+Hydrochlorothiazide	Market penetration, patent extension in specific formulations
Biosimilars	Develop biosimilar ARBs	Capturing emerging markets, reducing R&D costs
Novel Formulations	Extended-release, transdermal	Clinical differentiation, targeted niche markets

---

8. Conclusion and Actionable Insights

• Revenue Outlook: Expect a continued decline due to patent expiry and generic competition, with stabilization possible through niche strategies.
• Investment Focus: Diversify into combination therapies, biosimilars, and emerging markets to offset revenue erosion.
• Risk Management: Prioritize compliance, quality manufacturing, and litigation mitigation.
• Innovation Imperative: Invest in formulations and delivery systems to extend lifecycle and maintain competitive edge.
• Strategic Divestment & Partnership: Consider divestment of DIOVAN assets for non-core portfolios and seek alliances for pipeline development.

---

Key Takeaways

• DIOVAN's dominance has diminished significantly post-patent expiry, with generic competition eroding its market share.
• Regulatory restrictions and contamination recalls have heightened compliance costs and legal risks.
• Future revenue depends on portfolio diversification, formulation innovation, and expansion into biosimilars and niche markets.
• Stakeholders must balance cost-cutting with innovation investments to sustain profitability.
• A strategic shift toward combination therapies and emerging-market penetration offers the best prospects for stabilizing returns.

---

FAQs

Q1: How does patent expiration influence DIOVAN’s market share?
Patent expiry leads to generic entry, drastically reducing prices and market share for branded DIOVAN—typically by over 80% within five years post-expiration.

Q2: What are the regulatory challenges currently impacting DIOVAN?
Concerns over NDMA/NDEA contamination in valsartan formulations have resulted in recalls and increased scrutiny, impacting manufacturing and sales continuity.

Q3: What growth opportunities exist despite patent loss?
Developing fixed-dose combinations, biosimilars, extending formulations, and expanding in emerging markets present significant upside.

Q4: How do legal liabilities impact investment in DIOVAN?
Ongoing litigation and recall-related liabilities can inflate costs and diminish long-term profitability, warranting careful risk assessment.

Q5: Will DIOVAN regain market leadership in the future?
Unlikely in its current form; success depends on strategic pivoting towards innovative formulations and markets with less generic penetration.

---

References

[1] MarketResearch.com, "Global Hypertension Market Report 2022."
[2] Novartis Annual Reports, 2010-2022.
[3] FDA Drug Recalls, 2018-2020.